New treatment approach for advanced pancreatic cancer
Official title: TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
Funded at University of California at Davis · NIH-11044246 · Data updated 2026-11-12
This study is testing a new treatment for advanced pancreatic cancer that combines a special chemotherapy drug with immune boosters to help your body fight the cancer better, and it's designed for people with pancreatic ductal adenocarcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $77,924 |
| NIH project number | 3R01CA269233-03S1 |
| Project ID | NIH-11044246 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced pancreatic ductal adenocarcinoma who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage pancreatic cancer or those who have not been diagnosed with pancreatic cancer may not benefit from this research.
What this research studies
This research focuses on developing a combination treatment strategy for advanced pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA). The approach involves using a novel chemotherapy drug, TGX-1214, which is formulated as a nanoemulsion, in conjunction with immune checkpoint inhibitors. The research team, comprising experts from the University of California at Davis, TargaGenix, and Northeastern University, aims to enhance the effectiveness of this treatment by increasing immune cell infiltration into tumors. Preliminary studies have shown promising results in reducing tumor growth in preclinical models.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced pancreatic cancer.
How similar studies have gone: Other research has shown success with similar combination therapies in treating pancreatic cancer, indicating a promising avenue for further exploration.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Mackenzie, Gerardo Guillermo — University of California at Davis
- Study coordinator: Mackenzie, Gerardo Guillermo
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.